Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:54:14Z | |
dc.date.available | 2018-06-22T09:54:14Z | |
dc.date.issued | 2012 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42252 | |
dc.description.abstract | Cancer of unknown primary sites (CUP) is a compilation of various malignant entities-the majority of which behave aggressively and carry poor prognosis. CUP is classified into two different clinicopathological groups: the unfavourable (poor-prognosis) and the favourable (good-prognosis) group. Patients with favourable subsets are treated relevant to the hidden primary tumour chemotherapy regimens and/or radiotherapy. These patients exhibit better responses and prolonged survival. On the other hand, patients of unfavourable subsets are treated with various chemotherapy combinations of platinum- or taxane-containing regimens. Unfortunately, responses and overall survival in this group of CUP patient are not very promising. Several independent prognostic factors have been associated with survival of CUP patients. Since CUP is not an unknown disease, emerging therapeutic innovations are warranted. © The author 2012. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. | en |
dc.language.iso | eng | en |
dc.source | Annals of Oncology | en |
dc.subject | Article | en |
dc.subject | Antineoplastic agent | en |
dc.subject | Cisplatin | en |
dc.subject | Cyclophosphamide | en |
dc.subject | Doxorubicin | en |
dc.subject | Etoposide | en |
dc.subject | Fluorouracil | en |
dc.subject | Human | en |
dc.subject | Mitomycin | en |
dc.subject | Neoplasms | en |
dc.subject | Adenocarcinoma | en |
dc.subject | Humans | en |
dc.subject | Breast cancer | en |
dc.subject | Cancer survival | en |
dc.subject | Carboplatin | en |
dc.subject | Paclitaxel | en |
dc.subject | Priority journal | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Drug efficacy | en |
dc.subject | Gemcitabine | en |
dc.subject | Taxoids | en |
dc.subject | Treatment outcome | en |
dc.subject | Prognosis | en |
dc.subject | Cancer staging | en |
dc.subject | Docetaxel | en |
dc.subject | Erlotinib | en |
dc.subject | Metastasis | en |
dc.subject | Overall survival | en |
dc.subject | Cancer prognosis | en |
dc.subject | Cancer radiotherapy | en |
dc.subject | Bone metastasis | en |
dc.subject | Epirubicin | en |
dc.subject | Folinic acid | en |
dc.subject | Irinotecan | en |
dc.subject | Platinum complex | en |
dc.subject | Carcinoma | en |
dc.subject | Clinical feature | en |
dc.subject | Lymphatic metastasis | en |
dc.subject | Histopathology | en |
dc.subject | Disease association | en |
dc.subject | Treatment response | en |
dc.subject | Treatment | en |
dc.subject | Bevacizumab | en |
dc.subject | Altretamine | en |
dc.subject | Squamous cell carcinoma | en |
dc.subject | Cancer of unknown primary site | en |
dc.subject | Unknown primary | en |
dc.subject | Cancer localization | en |
dc.subject | Prostate specific antigen | en |
dc.subject | Neuroendocrine tumor | en |
dc.subject | Cervical lymph node | en |
dc.subject | Peritoneum cancer | en |
dc.subject | Clinical effectiveness | en |
dc.subject | Cancer of unknown primary | en |
dc.subject | Anthracyclines | en |
dc.subject | Colon adenocarcinoma | en |
dc.subject | Ovary carcinoma | en |
dc.subject | Platinum | en |
dc.subject | Vindesine | en |
dc.subject | Capecitabine plus oxaliplatin | en |
dc.subject | Clinicopathological subsets | en |
dc.subject | Liver cancer | en |
dc.title | Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1093/annonc/mds317 | |
dc.description.volume | 23 | |
dc.description.issue | SUPPL. 10 | en |
dc.description.startingpage | x282 | |
dc.description.endingpage | x285 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |